Skip to main content
NewslettersWatchlist

Cipher Pharmaceuticals Inc(CPH-T)
TSX

Today's Change
Real-Time Last Update
Day Low8.52
Day High8.89
Open:8.52
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Cipher Pharmaceuticals Inc up on Tuesday (CPH)
AI-generated - The Globe and Mail
Cipher Pharmaceuticals: Stocks Overvalued by Analyst Consensus on TSX (CPH)
Baystreet
Stocks in play: Cipher Pharmaceuticals
Newsfile
Cipher Pharmaceuticals Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference
AI-generated - The Globe and Mail
Cipher Pharmaceuticals: Stocks Overvalued by Analyst Consensus on TSX (CPH)
AI-generated - The Globe and Mail
Cipher Pharmaceuticals: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CPH)
Newswire.ca
Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results
Newswire.ca
Cipher Pharmaceuticals Schedules Q4 2023 Earnings Release and Conference Call
AI-generated - The Globe and Mail
Cipher Pharmaceuticals: Stocks Overvalued by Analyst Consensus on TSX (CPH)
AI-generated - The Globe and Mail
Cipher Pharmaceuticals: Stocks Overvalued by Analyst Consensus on TSX (CPH)
AllPennyStocks.com
Will Uplisting Be the Catalyst to Send Shares of this Pharma Company Higher?
Newswire.ca
Cipher Pharmaceuticals Announces the Commencement of OTCQX Trading
GlobeNewswire
OTC Markets Group Welcomes Cipher Pharmaceuticals Inc. to OTCQX
AI-generated - The Globe and Mail
Cipher Pharmaceuticals: Stocks Overvalued by Analyst Consensus on TSX (CPH)
Newswire.ca
Cipher Pharmaceuticals Announces Change of Auditor
Newswire.ca
Cipher Pharmaceuticals Announces Normal Course Issuer Bid
Newswire.ca
Cipher Pharmaceuticals Reports Strong Sales & Earnings Growth in Q3 2023
AI-generated - The Globe and Mail
Cipher Pharmaceuticals: Stocks Overvalued by Analyst Consensus on TSX (CPH)
Newswire.ca
Cipher Pharmaceuticals Schedules Q3 2023 Earnings Release and Conference Call
Newswire.ca
Cipher Pharmaceuticals Announces Final Results of Substantial Issuer Bid
Baystreet
Stocks in play: Cipher Pharmaceuticals Inc.
Newswire.ca
Cipher Pharmaceuticals Provides Reminder of the Upcoming Expiration of its Substantial Issuer Bid
Newswire.ca
Cipher Pharmaceuticals Announces Intention to Commence Substantial Issuer Bid, Aggregate Price up to $6 Million Canadian Dollars
Newswire.ca
Cipher Pharmaceuticals Releases Q2 2023 Results, Announces Launch of Epuris in Mexico
Baystreet
Stocks in play: Cipher Pharmaceuticals Inc.
Newswire.ca
Cipher Pharmaceuticals Schedules Q2 2023 Earnings Release and Conference Call
Baystreet
Stocks in play: Cipher Pharmaceuticals Inc.
Newswire.ca
Cipher Partner, Moberg Pharma Announces Approval for MOB-015 in the European Union
Newswire.ca
Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders
Newswire.ca
Cipher Pharmaceuticals Reports First Quarter Results, Highlighted by Record Cash Per Share and Strong Financial Flexibility
Newswire.ca
Cipher Pharmaceuticals Schedules Q1 2023 Earnings Release and Conference Call
Newsfile
Cipher Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products among others. The company's geographical operational areas include Canada and the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.